<DOC>
	<DOCNO>NCT02050828</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy AKB-9778 administer daily subcutaneous injection without monthly intravitreal injection ranibizumab 3 month patient diabetic macular edema .</brief_summary>
	<brief_title>The TIME-2 Study : A Phase 2 Study AKB-9778 , Novel Tie-2 Activator , Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>The following abbreviated list inclusion criterion : Adults 18 80 year age , inclusive Diagnosis diabetes mellitus ( type 1 type 2 ) Decrease vision study eye determine primarily result DME Definite retinal thickening due diffuse DME involve central macula study eye Central subfield thickness least 325 µm sdOCT presence intraretinal fluid study eye ETDRS BCVA letter score ≤ 76 ≥ 24 study eye The following abbreviated list exclusion criterion : Hemoglobin A1C ( HbA1C ) ≥ 12.0 % Screening History non infectious uveitis Decrease visual acuity due cause DME study eye History follow study eye ( however , follow exclusionary fellow eye ) : 1 . Prior par plana vitrectomy 2 . Any ocular surgery within 3 month prior Day 1 3 . YAG capsulotomy within 3 month prior Day 1 4 . Panretinal scatter photocoagulation ( PRP ) focal laser within 3 month prior Day 1 anticipate need PRP course study 5 . Prior intravitreal , subtenon , periocular steroid therapy within 3 month prior Day 1 6 . Prior treatment intravitreal antivascular endothelial growth factor ( VEGF ) treatment within 8 week prior Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>